Implications of MMP-12 in the pathophysiology of ischaemic stroke  

作　　者：Krishna Kumar Veeravalli 

机构地区：[1]Cancer Biology and Pharmacology,University of Illinois College of Medicine at Peoria,Peoria,Illinois,USA

出　　处：《Stroke & Vascular Neurology》2024年第2期97-107,共11页卒中与血管神经病学（英文）

基　　金：The National Institute of Neurological Disorders and Stroke of the National Institutes of Health awarded a research grant(Award Number:R01NS102573)to study the role of MMP-12 in ischaemic stroke.

摘　　要：This article focuses on the emerging role of matrix metalloproteinase-12(MMP-12)in ischaemic stroke(IS).MMP-12 expression in the brain increases dramatically in animal models of IS,and its suppression reduces brain damage and promotes neurological,sensorimotor and cognitive functional outcomes.Thus,MMP-12 could represent a potential target for the management of IS.This article provides an overview of MMP-12 upregulation in the brain following IS,its deleterious role in the post-stroke pathogenesis(blood-brain barrier disruption,inflammation,apoptosis and demyelination),possible molecular interactions and mechanistic insights,its involvement in post-ischaemic functional deficits and recovery as well as the limitations,perspectives,challenges and future directions for further research.Prior to testing any MMP-12-targeted therapy in patients with acute IS,additional research is needed to establish the effectiveness of MMP-12 suppression against IS in older animals and in animals with comorbidities.This article also examines the clinical implications of suppressing MMP-12 alone or in combination with MMP-9 for extending the currently limited tissue plasminogen activator therapy time window.Targeting of MMP-12 is expected to have a profound influence on the therapeutic management of IS in the future.

关 键 词：INVOLVEMENT ALONE DIRECTIONS 

分 类 号：R743.3[医药卫生—神经病学与精神病学]